Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2000

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 10 I, 2001, Pages 1789-1804

  Tobin, Martin J ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA CAROTENE; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA CAROTENE; BRONCHODILATING AGENT; CAROTENOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOCORTICOID; GLYCERYL TRINITRATE; LOW MOLECULAR WEIGHT HEPARIN; LYCOPENE; MILRINONE; MONOCROTALINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NADROPARIN; NITRIC OXIDE; OXITROPIUM BROMIDE; OZONE; ROLIPRAM; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIPTOLIDE; UNINDEXED DRUG; VASCULOTROPIN; ZAPRINAST;

AIR POLLUTION; ALTITUDE; BREATHING; BREATHING MUSCLE; BRONCHIOLITIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE MARKER; ENZYME DEFICIENCY; EXERCISE; EXHAUST GAS; GENETIC SUSCEPTIBILITY; HEALTH CARE DELIVERY; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG EMBOLISM; LUNG RESECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PLEURA DISEASE; PNEUMONIA; PRIORITY JOURNAL; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SMOKING CESSATION;

EID: 0035891607     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.10.2108126     Document Type: Review

References (130)

1. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease
2. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease
3. 1- antitrypsin deficiency
4. 1-antitrypsin heterozygotes of phenotype PiMZ
5. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease
6. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease
7. Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease
8. Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease
9. Serum carotenoids, α-tocopherol, and lung function among Dutch elderly
10. Longitudinal follow-up study of smoking-induced lung density changes by high-resolution computed tomography
11. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation
12. The distribution of neurokinin-1 and neurokinin-2 receptors in human central airways
13. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10
14. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis
15. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease
16. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease
17. Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale. Correlates with echo-Doppler assessment
18. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways
19. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease
20. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease
21. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers
22. Peripheral airway smooth muscle mechanics in obstructive airways disease
23. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function
24. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study
25. Pulmonary blood flow distribution in stage 1 chronic obstructive pulmonary disease
26. The Fick principle and the steady state
27. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease
28. Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship
29. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease
30. Respiratory muscle recruitment and exercise performance in eucapnic and hypercapnic severe chronic obstructive pulmonary disease
31. Respiratory muscle endurance training in chronic obstructive pulmonary disease: Impact on exercise capacity, dyspnea, and quality of life
32. Noninvasive assessment of inspiratory muscle function during exercise
33. Diaphragmatic fatigue and high-intensity exercise in patients with chronic obstructive pulmonary disease
34. Quadriceps fatigue after cycle exercise in patients with chronic obstructive pulmonary disease
35. Altered glutamate metabolism is associated with reduced muscle glutathione levels in patients with emphysema
36. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease
37. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease
38. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease
39. Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease
40. Are elderly patients with obstructive airway disease being prematurely discharged?
41. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease
42. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
43. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests
44. 1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease
45. Withdrawal of chronic systemic corticosteroids in patients with COPD: A randomized trial
46. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease
47. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease
48. Rebuttal
49. Rebuttal
50. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease
51. Acute respiratory failure after lung volume reduction surgery
52. Lung volume reduction surgery does not improve diaphragmatic contractile properties or atrophy in hamsters with elastase-induced emphysema
53. 1-antitrypsin deficiency
54. 1-antitrypsin deficiency
55. Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease
56. Noninvasive ventilation has not been shown to be ineffective in stable COPD
57. Noninvasive ventilation has been shown to be ineffective in stable COPD
58. Rebuttal
59. Rebuttal
60. The human bone marrow response to acute air pollution caused by forest fires
61. Concentrated ambient air particles induce mild pulmonary inflammation in healthy human volunteers
62. Resistance of very young mice to inhaled allergen sensitization is overcome by coexposure to an air-pollutant aerosol
63. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects
64. The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies
65. Ozone-induced epithelial injury in the ferret is similar to nonhuman primates
66. Ozone, but not nitrogen dioxide, exposure decreases glutathione peroxidases in epithelial lining fluid of human lung
67. Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8
68. Diesel exhaust particles activate p38 MAP kinase to produce interleukin 8 and RANTES by human bronchial epithelial cells and N-acetylcysteine attenuates p38 MAP kinase activation
69. Acute exposure to diesel exhaust increases IL-8 and GRO-α production in healthy human airways
70. Exposure to diesel exhaust aggravates nasal allergic reaction in guinea pigs
71. Airway inflammation after controlled exposure to diesel exhaust particulates
72. What constitutes an adverse health effect of air pollution? Official statement of the American Thoracic Society
73. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33
74. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing
75. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy
76. Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans. A positron emission tomography study
77. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats
78. Hypertensive pulmonary vascular disease: Dawn of the age of prevention?
79. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study
80. Pulmonary veno-occlusive disease
81. A noninvasive diagnostic strategy including spiral computed tomography in patients with suspected pulmonary embolism
82. "High probability" perfusion lung scans in pulmonary venoocclusive disease
83. Diagnostic value of arterial blood gas measurement in suspected pulmonary embolism
84. Diagnosing acute pulmonary embolism: Effect of chronic obstructive pulmonary disease on the performance of D-dimer testing, ventilation/perfusion scintigraphy, spiral computed tomographic angiography, and conventional angiography
85. Spiral computed tomography is comparable to angiography for the diagnosis of pulmonary embolism
86. Endothelial nitric oxide synthase function in pig lung after chronic pulmonary artery obstruction
87. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD
88. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy
89. Operation Everest III (Comex '97): Modifications of cardiac function secondary to altitude-induced hypoxia. An echocardiographic and Doppler study
90. Exhaled nitric oxide in high-altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammation
91. Stumbling over a bias. What happens to spinal fluid pH at high altitude?
92. Dynamic changes in apoptotic and necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation
93. Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs
94. Beneficial effect of lung preservation is related to ultrastructural integrity of tubular myelin after experimental ischemia and reperfusion
95. Cytoprotective effects of nitroglycerin in ischemia-reperfusion-induced lung injury
96. Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts
97. Targeting the angiotensin system in posttransplant airway obliteration: The antifibrotic effect of angiotensin converting enzyme inhibition
98. RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration
99. Dendritic cells and macrophages in lung allografts: A role in chronic rejection?
100. Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis
101. Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts
102. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell findings
103. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution
104. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar layage fluid are associated with the development of obliterative bronchiolitis after lung transplantation
105. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase
106. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life
107. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis
108. Airway complications following pediatric lung and heart-lung transplantation
109. Outcome of patients with cystic fibrosis awaiting lung transplantation
110. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage
111. Inducible nitric oxide synthase-knockout mice exhibit resistance to pleurisy and lung injury caused by carrageenan
112. Measurement of pleural pressure during therapeutic thoracentesis
113. Talc induces apoptosis in human malignant mesothelioma cells in vitro
114. 2 produces an excellent pleurodesis in rabbits
115. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions
116. Talc should be used for pleurodesis
117. Talc should not be used for pleurodesis
118. Rebuttal
119. Rebuttal
120. Management of malignant pleural effusions
121. Pneumoconiosis-related lung cancers: Preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis
122. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study
123. Does idiopathic pulmonary fibrosis increase lung cancer risk?
124. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis
125. Smoking and lung cancer
126. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer
127. The utility of transbronchial needle aspiration in the staging of bronchogenic carcinoma
128. Evaluation and management of the solitary pulmonary nodule
129. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer
130. Molecular and genetic aspects of lung cancer